ICON vs Neurocrine Biosciences

ICON (ICLR), health care, and Neurocrine Biosciences (NBIX), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Neurocrine Biosciences is worth $16.8B on the stock market and ICON $14.6B: Neurocrine Biosciences is valued at 15% more. ICON trades at 78.0 times earnings and Neurocrine Biosciences at 24.6; operating margins in their latest fiscal years were 5.37% and 21.6%. Over the past year ICON's share price has moved +18.9% and Neurocrine Biosciences's +19.2%.

Key facts

ICON market value
$14.6B
Neurocrine Biosciences market value
$16.8B
ICON P/E
78.0
Neurocrine Biosciences P/E
24.6
ICON revenue
$8.3BFY to 2025-12-31
Neurocrine Biosciences revenue
$2.9BFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

ICON vs Neurocrine Biosciences: every measure side by side
Measure ICON Neurocrine Biosciences
SectorHealth CareHealth Care
Country Ireland United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$14.6Blower$16.8Bhigher
Revenue$8.3Bhigher$2.9Blower
Earnings$229.3Mlower$478.6Mhigher
Employees40,250higher2,500lower
Total assets$16.3Bhigher$4.6Blower
Valuation
P/E78.0higher24.6lower
P/S1.8lower5.9higher
P/B—4.3
Dividend yield—0.00%
Profitability
Operating margin5.37%lower21.6%higher
Balance sheet
Net assets$9.2Bhigher$3.3Blower
Total liabilities$7.1Bhigher$1.4Blower
Total debt$2.9B—
Cash on hand$647.3Mlower$713Mhigher
Price change
Today+1.89%higher+0.37%lower
1 year+18.9%lower+19.2%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio. Who owns ICLR · Who owns NBIX

Further comparisons

Learn

Questions and answers

Which is bigger, ICON or Neurocrine Biosciences?

By market value, Neurocrine Biosciences is the larger: $16.8B against $14.6B for ICON. By revenue in its latest fiscal year, ICON is the larger: $8.3B against $2.9B for Neurocrine Biosciences.

Which has the higher P/E ratio?

ICON: 78.0, against 24.6 for Neurocrine Biosciences. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher operating margin?

Neurocrine Biosciences: 21.6%, against 5.37% for ICON. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which superinvestors own both ICON and Neurocrine Biosciences?

None of the tracked superinvestors holds both in their latest 13F filing. 13 hold ICON and 5 hold Neurocrine Biosciences.

Cite this page

Funkfolio, “ICON vs Neurocrine Biosciences”, data as of 18 November 2026. https://funkfolio.com/compare/iclr-vs-nbix

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.